Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines

Infection and Immunity

Volumn 64, Issue 4, 1996, Pages 1454-1457

  Kollaritsch, H ^a   Furer E ^b   Herzog, C ^b   Wiedermann, G ^a   Que, J U ^b   Cryz Jr , S J ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b Berna Biotech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CHOLERA VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; SALMONELLOSIS VACCINE;

ABDOMINAL CRAMP; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SAFETY; SALMONELLA TYPHI; SEROCONVERSION; VACCINATION; VIBRIO CHOLERAE; VOMITING;

EID: 0029879171     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.64.4.1454-1457.1996     Document Type: Article

References (30)

1. Ambrosch, F., A. Hirschl, P. Kremsner, M. Kundi, C. Kunz, E. Rappold, and G. Wiedermann. 1985. Orale Typhus-Lebendimpfung. Neuere Aspekte, Muench. Med. Wochenzeitschr. 127:775-778
2. Barret, P., P. Clarke, and S. J. Cryz, Jr. 1993. Oral cholera vaccine well tolerated Br Med. J. 307:1425.
3. Centers for Disease Control. 1992. Cholera associated with international travel, 1992. Morbid Mortal. Weekly Rep. 41:664-667
4. Clements, J. D., F. van Loon, D. A. Sack, J. Chakraborty, M. R. Rao, F. Ahmed, J. R. Harris, M. R. Khan, M. Yunus, S. Huda, B. A. Kay, A.-M. Svennerholm, and J. Holmgren. 1991 Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J. Infect. Dis 163:1235-1242.
5. Clements, M. L., M. M. Levine, C. R. Young, R. E. Black, Y.-L. Lim, and R. M. Robins-Browne. 1982. Magnitude, kinetics and duration of vibriocidal antibody response in North Americans after ingestion of Vibrio cholerae. J. Infect. Dis. 145:465-473.
6. Cryz, S. J., Jr. 1990. Post-marketing experience with live oral Ty21a. Lancet 341:49-50.
7. Cryz, S. J., Jr., M. M. Levine, J. B. Kaper, E. Fürer, and B. Althaus. 1990. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine 8:577-580.
8. Cryz, S. J., Jr., M. M. Levine, G. A. Losonsky, J. B. Kaper, and B. Althaus. 1992 Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults. Infect. Immun. 60:3916-3917.
9. Cryz, S. J., Jr., J. U. Que, M. M. Levine, G. Wiedermann, and H. Kollaritsch. 1995. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio choleras CVD 103-HgR) vaccine in healthy adults. Infect Immun. 63:1336-1339.
10. Cryz, S. J., Jr., N. Vanprapaz, U. Thisyakorn, T. Olanratmance, G. Losonsky, M. M. Levine, and S. Chearskul. 1993. Safety and immunogemcity of Salmonella typhi Ty21a vaccine in young Thai children. Infect. Immun. 61: 1149-1151.
11. Glass, R. I., A.-M. Svennerholm, M. R. Khan, S. Huda, M. I. Huq, and J. Holmgren. 1985. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection J. Infect. Dis. 151:236-246.
12. Gotuzzo, E., B. Butron, C. Seas, M. Penny, R. Ruiz, G. Losonsky, C. F. Lanata, S. S. Wasserman, E. Salazar, J. B. Kaper, S. J. Cryz, Jr., and M. M. Levine. 1993. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low. socioeconomic levels. Infect. Immun. 61:3994-3997.
13. Gupta, B. L., R. A. Bhujwala, and Shriniwas. 1990. Multiresistant Salmonella typhi in India. Lancet 336:252.
14. Kotloff, K. L., S. S. Wasserman, S. O'Donnell, G. A. Losonsky, S. J. Cryz, Jr., and M. M. Levine. 1992. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind, crossover trial. Infect. Immun. 60:4430-4432.
15. Levine, M. M., C. Ferreecio, R. E. Black, C. O. Tacket, R. Germanier, and The Chilean Typhoid Committee. 1989. Progress in vaccines against typhoid fever Rev. Infect. Dis. 11(Suppl. 3):S552-S567.
16. Levine, M. M., C. Ferreecio, S. J. Cryz, Jr., and E. Ortiz. 1990. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in a randomized controlled field trial. Lancet 336:891-894.
17. Levine, M. M., D. Herrington, J. R. Murphy, J. G. Morris, G. Losonsky, B. Tall, A. Lindberg, S. Svenson, S. Baqar, M. F. Edwards, and B. Stocker. 1987. Safety, infectivity, immunogenicity and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541 Ty and 543 Ty. as live oral vaccines in man. J. Clin. Invest. 79:888-902
18. Levine, M. M., and J. Kaper. 1993. Live vaccines against cholera: an update Vaccine 11:207-212.
19. Levine, M. M., J. Kaper, D. Herrington, J. Ketley, G. Losonsky, C. O. Tacket, B. Tall, and S. J. Cryz, Jr. 1988 Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet ii:467-470.
20. Nossal, G. 1993. Prospects for new vaccines. World Health 46:7-9.
21. Olanratmanee, T., M. Levine, G. Losonsky, U. Thisyakorn, and S. J. Cryz, Jr. 1992. Safety and immunogenicity of Salmonella Typhi Ty21a liquid formulation vaccine in 4 to 6-year-old Thai children. J. Infect. Dis 166:451-152
22. Siddique, A. K., A. Salam, M. S. Islam, K. Akram, R. N. Majumdar, K. Zaman, N. Fronczak, and S. Laston. 1995. Why treatment centres failed to prevent cholera deaths, among Rwandan refugees in Coma, Zaire Lancet 345:359-361
23. Simanjuntak, C. H., P. O'Hanley, N. H. Punjabi, F. Noriego, G. Pazzaglia, P. Dykstra, B. Kay, C. Suharyono, A. Budiarso, A. R. Rifai, S. S. Wasserman, G. Losonsky, J. Kaper, S. J. Cryz, Jr., and M. M. Levine. 1993. Safety immunogenicity, and transmissibility of single-dose CVD 103-HgR in 24- to 59-month-old Indonesian children J Infect. Dis 168:1169-1176
24. Simanjuntak, C. H., F. P. Paleologo, N. H. Punjabi, R. Darmowigoto, S. H. Totosudirjo, P. Haryanto, E. Suprijanto, N. D. Witham, and S. L. Hoffman. 1991. Oral immunization against typhoid fever m Indonesia with Ty21a vaccine. Lancet 338:1055-1059
25. Su-Arehawatana, P., P. Singharaj, D. Taylor, et al. 1992. Safety and immu-nogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J. Infect. Dis. 165:1042-1048.
26. Suharyono, C., C. Simanjuntak, N. Witham, N. Punjabi, D. Gray Heppner, G. Losonsky, H. Totosudirjo, A. R. Rifai, J. Clemens, Y. L. Lim, D. Burr, S. S. Wasserman, J. Kaper, K. Sorenson, S. J. Cryz, Jr., and M. M. Levine. 1992. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9 year-old Indonesian children. Lancet 340:689-694.
27. Tacket, C. O., G. Losonsky, J. P. Nataro, S. J. Cryz, Jr., R. Edelman, J. B. Kaper, and M. M. Levine. 1992. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 166:837-841.
28. Taylor, D. N., R. A. Pollard, and P. A. Blake. 1983. Typhoid in the United States and the risk to the international traveller. J. Infect. Dis. 148:599-602.
29. Threefall, E. J., B. Said, B. Rowe, and A. Dávalos-Pérez. 1993. Emergence of multiple drug resistance in Vibrio cholerae 01 El Tor from Ecuador. Lancet 342:1173.
30. World Health Organization. 1992. Infected areas as of 28 November, 1991. Epidemiol Rec. W. H. O 48:358-360.